Praveen Tyle, Ph. D. is currently Senior Vice President & Global Head of R&D and BD&L OTC for Novartis Consumer Health Care, Parsippany, NJ. Dr. Tyle joined Novartis in June 2008 from Bausch & Lomb's where he served, from 2004-2008, as corporate senior vice president - Global Research and Development and Chief Scientific Officer, responsible for the Company's research, new product development, preclinical development, project management, clinical, medical and regulatory affairs, and product quality.
Dr. Tyle has 26 years of drug development and commercialization experience. He began his professional career as a formulations research chemist in drug delivery research with American Cyanamid Company (now Wyeth), moving on to executive leadership and scientific positions with Sandoz Pharmaceuticals (now Novartis), Agouron Pharmaceuticals (now Pfizer) and Aronex Pharmaceuticals (now Antigenics). In 1999, Dr. Tyle was named vice president - pharmaceutical sciences, U.S., Pharmacia & Upjohn (now Pfizer) and then named in 2001 as global vice president and global head - pharmaceutical sciences at Pharmacia Corporation. He joined Biovail in 2003 where he was group vice president - pharmaceutical sciences and manufacturing.
Dr. Tyle holds academic appointments as an adjunct professor of Ophthalmology at the University of Rochester Eye Institute, as well as an adjunct professor of Pharmacy at the University of Rhode Island, at the Howard University, Washington DC, and at the University of Houston, Texas. He is editor of seven books about drug development, holds several patents and is the author of more than 125 technical and scientific papers and presentations.
Dr. Tyle was born in Hapur, India, in March 1960. He holds a doctorate in Pharmaceutics and Pharmaceutical Chemistry from The Ohio State University (1984) and a bachelor of Pharmacy (honors) degree from the Institute of Technology, Banaras Hindu University, India (1980). Dr. Tyle is a member of the Board of Directors for Orient Europharma Ltd., Taiwan, and of EyeGate Pharmaceuticals, Inc., Waltham, MA. He is also a Scientific Advisory Board member of VioQuest Pharmaceuticals, Inc., New Jersey and Health Care Advisory Board of Arsenal Capital Partners, New York, NY.